Constantin F. Pixberg

Dr. Constantin F. Pixberg

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2023 in Breast Care
Verified
Journal Article
Closed access
PDF file
CPConstantin F. Pixberg
Constantin F. Pixberg
MSMarkus Schulze
Markus Schulze
LBLars Buschhorn
Lars Buschhorn
JSJan Philip Suppelna
Jan Philip Suppelna
AMAndreas Mock
Andreas Mock
ASAndreas Schneeweiss
Andreas Schneeweiss
Background: Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug use. Here, we describe the current challenges and our experience with reimbursement of molecular therapies in mBC. Methods: A total of 100 applications for reimbursement of off-label therapies recommended by an iMTB were filed for patients with mBC, of which 89 were evaluable for this analysis. The approval rate was correlated with the molecular level of evidence of the respective therapy according to the National Center for Tumor Diseases (NCT) and European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) classification as well as with pretreatment therapy lines. Findings: Overall, 53.9% (48/89) of reimbursement applications were approved. Applications for therapies based on level of evidence m1 (NCT classification), tier I and II (ESCAT classification) had a significantly and clinically relevant increased chance of reimbursement, while a greater number of previous treatment lines had no significantly increased chance of approval, though a trend of approval toward higher treatment lines was detectable. Interpretation: Currently, the German jurisdiction seems to aggravate the clinical implementation of clinically urgently needed molecular therapies.

14 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TWThomas Walle
Thomas Walle
EEErkin Erdal
Erkin Erdal
LMLeon Muehlsteffen
Leon Muehlsteffen
HSHans Martin Singh
Hans Martin Singh
EGEditha Gnutzmann
Editha Gnutzmann
EWEva C. Winkler
Eva C. Winkler
Background: Mobile phone video call applications generally did not undergo testing in randomized controlled clinical trials prior to their implementation in patient care regarding the rate of successful patient visits and impact on the physician-patient relationship. Methods: The NCT MOBILE trial was a monocentric open-label randomized controlled clinical trial of patients with solid tumors undergoing systemic cancer therapy with need of a follow-up visit with their consulting physician at outpatient clinics. 66 patients were 1:1 randomized to receive either a standard in-person follow-up visit at outpatient clinics or a video call via a mobile phone application. The primary outcome was feasibility defined as the number of successful appointments at the first follow up visit. Secondary outcomes included success rate of further video calls, time spent by patient and physician, patient satisfaction, and quality of physician-patient relationship. Findings: Success rate of the first follow up visit in the intention-to-treat cohort was 87.8% for in-person visits and 78.7% for video calls (p=0.51, RR=0.88-1.43 95%CI). The most common reasons for failure were software incompatibility (12%) in the video call and no-show (6%) in the in-person visit arm. The success rate for further video visits was 91.6% (11 of 12 calls). Standardized patient questionnaires showed significantly decreased total time spent and less direct costs for patients (Δ95 to 246min 95%CI, Δ4.8 to 23.9€ 95%CI) and comparable time spent for physicians in the video call arm (Δ-6.4 to 5.4min, 95%CI). Doctor-patient relationship quality mean scores assessed by the validated standardized “questionnaire on quality of physician-patient interaction”(QQPPI) were higher in the video call arm (video call/in-person = 1.12 fold, p=0.02). Interpretation: Follow-up visits with the tested mobile phone video call application were feasible but software compatibility should be critically evaluated. Trial registration: Retrospectively registered in the German Clinical Trials Register DRKS00015788, 26 th October 2018